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Background:  Acute exacerbation of heart failure (HF) in patients with preserved ejection fraction (EF) often have deterioration of renal function 
secondary to use of diuretics. There are no previous studies about the role of nesiritide in diastolic HF patients. The aim of this study was to examine 
the effect of nesiritide on renal function at 48 hours, day of discharge and three weeks after administration.
Methods:  We conducted a retrospective study of 376 patients with heart failure with preserved LV systolic function documented by transthoracic 
echocardiogram and renal insufficiency between November 2006 and March 2010. Of these 192 patients were admitted at Loma Linda University 
Medical Center for Acute Decompensated Heart Failure (ADHF) and treated with IV Nesiritide and another 184 patients with decompensated 
diastolic heart failure treated only with IV furosemide (control). Chronic renal insufficiency was defined as GFR<60 ml/min/1.73m2 by MDRD 
method for at least six months. Serum creatinine and GFR levels at baseline, 48 hours, time of discharge and three weeks after nesiritide or IV 
furosemide were assessed respectively for both groups.
Results:  In the nesiritide group, there was a significant mean GFR decrease of 2.64 ± 16.8, p < 0.001 at 48 hours as well as 3.38 ± 17.53, p < 
0.001 at day of discharge but the GFR remained stable (p = 0.330) at three weeks post nesiritide infusion (fig 1). In the control group there was a 
significant deterioration of kidney function at all time points including three weeks. There was a significant difference between nesiritide and control 
group in the mean change of GFR at three weeks after (1.00 ± 18.65 vs. -3.17 ± 14.26, p < 0.001) respectively. Similar results were noted for both 
groups when we used serum creatinine data.
Conclusions:  Nesiritide has a good and protective renal effect in patients admitted with decompensated diastolic HF at three weeks post 
nesiritide administration as compared to significant deterioration of creatinine and GFR when treated with intravenous Furosemide.
